Phase III STEP Young shows BMI reduction in obese children aged 6-12, 40.4% no longer obese; faces Lilly competition and patent cliffs
첫날 -3.1% · 5일 후 -5.8%
›전개 과정 2회
2026-09-07Two independent reports confirm primary endpoint met in children 6-12, potentially expanding Wegovy's label
2026-09-09Phase III STEP Young shows BMI reduction in obese children aged 6-12, 40.4% no longer obese; faces Lilly competition and patent cliffs
기업악재
Novo Nordisk halts two more heart drug trials, diversification setback영어 원문
Two ziltivekimab trials halted, underscoring reliance on obesity franchise for growth
첫날 -3.1% · 5일 후 -5.8%
제품
Novo Nordisk's Oral Wegovy Launches in Germany, Zava Begins Delivery영어 원문
Zava confirms delivery of oral Wegovy in Germany, aligning with EU-first launch and advancing commercialization
첫날 -0.5% · 5일 후 -1.2%
›전개 과정 2회
2026-09-01Oral Wegovy launched in Germany, first EU country, expanding weight-loss drug market reach
2026-09-03Zava confirms delivery of oral Wegovy in Germany, aligning with EU-first launch and advancing commercialization
규제
FDA Warns on Compounded GLP-1 Risks, Novo Nordisk in Focus영어 원문
FDA cites 30 firms, HIMS falls, LLY and NVO in focus
첫날 +3.7% · 5일 후 -5.9%
›전개 과정 2회
2026-09-02FDA warning letters ban retatrutide and cagrilintide in compounding, impacting GLP-1 market
2026-09-03FDA cites 30 firms, HIMS falls, LLY and NVO in focus
애널리스트악재
Deutsche Bank downgrades Novo Nordisk to Sell, shares down 70% from peak영어 원문
Growth concerns mount; Wall Street had been reluctant to advise selling
첫날 -1.4% · 5일 후 +2.2%
제품
China regulator accepts oral Wegovy application; competition persists영어 원문
After Lilly oral approval, Novo advances oral weight-loss drug in China
첫날 -1.8% · 5일 후 +1.9%
›전개 과정 2회
2026-08-14Eli Lilly's Foundayo, Europe's first oral GLP-1 approval with no food restrictions, directly challenges Novo Nordisk's oral Wegovy
2026-08-26After Lilly oral approval, Novo advances oral weight-loss drug in China
기업
Novo Nordisk Starts Study for Lowest Effective Wegovy Pill Dose영어 원문
New study tests lower doses, potentially expanding oral weight-loss drug access
첫날 +1.0% · 5일 후 -6.0%
›전개 과정 4회
2026-08-10Co-innovation hub in London to accelerate drug discovery
2026-08-11Oral GLP-1 competition intensifies; OASIS 5 start and UK approval of Lilly's pill both impact NVO's market position
2026-08-11Phase 3 trial for oral weight-loss drug expands pipeline amid competitive pressure.
2026-08-19New study tests lower doses, potentially expanding oral weight-loss drug access
애널리스트악재
Berenberg Cuts Novo Nordisk to Hold, PT Lowered to $47영어 원문
Analyst sees further multiple expansion requiring proof of obesity-pill lead and injectable growth
첫날 -1.7% · 5일 후 +0.2%
M&A·자금조달악재
First Trust Advisors Cuts Novo Nordisk Stake by 94.5% in Q1영어 원문
Institutional selling signals caution on Novo Nordisk's near-term outlook.
첫날 -1.2% · 5일 후 -3.1%
›전개 과정 2회
2026-08-11Institutional 13F filing shows major stake reduction, reflecting institutional flows
2026-08-11Institutional selling signals caution on Novo Nordisk's near-term outlook.
실적
Novo Nordisk Q2: Adjusted Sales Up 7%, GLP-1 Volume Supports but Prices Under Pressure영어 원문
Earnings call reveals latest results, completing the event line with prior guidance and stock reaction
첫날 +0.6% · 5일 후 +4.2%
›전개 과정 3회
2026-08-05Q2 profit beat and guidance hike failed to reassure, as Wegovy pill sales slightly missed and pipeline concerns persist, sending shares down over 5%.
2026-08-05CEO Doustdar pledges faster R&D and bolt-on acquisitions, but investors remain cautious on pipeline confidence.
2026-08-08Earnings call reveals latest results, completing the event line with prior guidance and stock reaction
제품악재
Eli Lilly Officially Sets Q1 2027 FDA Filing for Retatrutide, Intensifying Weight-Loss Competition영어 원문
Lilly reports 28.3% average weight loss over 80 weeks in phase 3, with official filing timeline, directly pressuring Novo Nordisk
첫날 +1.0% · 5일 후 -6.0%
›전개 과정 2회
2026-08-08Phase 3 shows 28.3% avg weight loss, outperforming rivals, posing direct threat to Novo Nordisk
2026-08-08Lilly reports 28.3% average weight loss over 80 weeks in phase 3, with official filing timeline, directly pressuring Novo Nordisk
규제호재
Texas Court Dismisses Strive Antitrust Suit Against Novo and Lilly영어 원문
Federal judge dismisses Strive antitrust suit; NVO rises nearly 2%
첫날 +2.8% · 5일 후 -2.9%
›전개 과정 2회
2026-08-07Court found no proof of blocked competition, easing legal overhang for Novo and Lilly.
Phase III STEP Young shows BMI reduction in obese children aged 6-12, 40.4% no longer obese; faces Lilly competition and patent cliffs
첫날 -3.1% · 5일 후 -5.8%
›전개 과정 2회
2026-09-07Two independent reports confirm primary endpoint met in children 6-12, potentially expanding Wegovy's label
2026-09-09Phase III STEP Young shows BMI reduction in obese children aged 6-12, 40.4% no longer obese; faces Lilly competition and patent cliffs
기업악재
Novo Nordisk halts two more heart drug trials, diversification setback영어 원문
Two ziltivekimab trials halted, underscoring reliance on obesity franchise for growth
첫날 -3.1% · 5일 후 -5.8%
제품
Novo Nordisk's Oral Wegovy Launches in Germany, Zava Begins Delivery영어 원문
Zava confirms delivery of oral Wegovy in Germany, aligning with EU-first launch and advancing commercialization
첫날 -0.5% · 5일 후 -1.2%
›전개 과정 2회
2026-09-01Oral Wegovy launched in Germany, first EU country, expanding weight-loss drug market reach
2026-09-03Zava confirms delivery of oral Wegovy in Germany, aligning with EU-first launch and advancing commercialization
규제
FDA Warns on Compounded GLP-1 Risks, Novo Nordisk in Focus영어 원문
FDA cites 30 firms, HIMS falls, LLY and NVO in focus
첫날 +3.7% · 5일 후 -5.9%
›전개 과정 2회
2026-09-02FDA warning letters ban retatrutide and cagrilintide in compounding, impacting GLP-1 market
2026-09-03FDA cites 30 firms, HIMS falls, LLY and NVO in focus
애널리스트악재
Deutsche Bank downgrades Novo Nordisk to Sell, shares down 70% from peak영어 원문
Growth concerns mount; Wall Street had been reluctant to advise selling
첫날 -1.4% · 5일 후 +2.2%
제품
China regulator accepts oral Wegovy application; competition persists영어 원문
After Lilly oral approval, Novo advances oral weight-loss drug in China
첫날 -1.8% · 5일 후 +1.9%
›전개 과정 2회
2026-08-14Eli Lilly's Foundayo, Europe's first oral GLP-1 approval with no food restrictions, directly challenges Novo Nordisk's oral Wegovy
2026-08-26After Lilly oral approval, Novo advances oral weight-loss drug in China
기업
Novo Nordisk Starts Study for Lowest Effective Wegovy Pill Dose영어 원문
New study tests lower doses, potentially expanding oral weight-loss drug access
첫날 +1.0% · 5일 후 -6.0%
›전개 과정 4회
2026-08-10Co-innovation hub in London to accelerate drug discovery
2026-08-11Oral GLP-1 competition intensifies; OASIS 5 start and UK approval of Lilly's pill both impact NVO's market position
2026-08-11Phase 3 trial for oral weight-loss drug expands pipeline amid competitive pressure.
2026-08-19New study tests lower doses, potentially expanding oral weight-loss drug access
애널리스트악재
Berenberg Cuts Novo Nordisk to Hold, PT Lowered to $47영어 원문
Analyst sees further multiple expansion requiring proof of obesity-pill lead and injectable growth
첫날 -1.7% · 5일 후 +0.2%
M&A·자금조달악재
First Trust Advisors Cuts Novo Nordisk Stake by 94.5% in Q1영어 원문
Institutional selling signals caution on Novo Nordisk's near-term outlook.
첫날 -1.2% · 5일 후 -3.1%
›전개 과정 2회
2026-08-11Institutional 13F filing shows major stake reduction, reflecting institutional flows
2026-08-11Institutional selling signals caution on Novo Nordisk's near-term outlook.
실적
Novo Nordisk Q2: Adjusted Sales Up 7%, GLP-1 Volume Supports but Prices Under Pressure영어 원문
Earnings call reveals latest results, completing the event line with prior guidance and stock reaction
첫날 +0.6% · 5일 후 +4.2%
›전개 과정 3회
2026-08-05Q2 profit beat and guidance hike failed to reassure, as Wegovy pill sales slightly missed and pipeline concerns persist, sending shares down over 5%.
2026-08-05CEO Doustdar pledges faster R&D and bolt-on acquisitions, but investors remain cautious on pipeline confidence.
2026-08-08Earnings call reveals latest results, completing the event line with prior guidance and stock reaction
제품악재
Eli Lilly Officially Sets Q1 2027 FDA Filing for Retatrutide, Intensifying Weight-Loss Competition영어 원문
Lilly reports 28.3% average weight loss over 80 weeks in phase 3, with official filing timeline, directly pressuring Novo Nordisk
첫날 +1.0% · 5일 후 -6.0%
›전개 과정 2회
2026-08-08Phase 3 shows 28.3% avg weight loss, outperforming rivals, posing direct threat to Novo Nordisk
2026-08-08Lilly reports 28.3% average weight loss over 80 weeks in phase 3, with official filing timeline, directly pressuring Novo Nordisk
규제호재
Texas Court Dismisses Strive Antitrust Suit Against Novo and Lilly영어 원문
Federal judge dismisses Strive antitrust suit; NVO rises nearly 2%
첫날 +2.8% · 5일 후 -2.9%
›전개 과정 2회
2026-08-07Court found no proof of blocked competition, easing legal overhang for Novo and Lilly.
